abstract |
The present invention relates to a pharmaceutical composition for transmucosal administration, comprising a peptide or protein drug in combination with an excipient with a pKa value of 12 or higher (e.g., arginine free base, EDTA tetrasodium salt, trisodium phosphate, tris(hydroxymethyl)aminomethane, lysine, or calcium hydroxide). |